Jagsonpal Pharmaceuticals Ltd has designated two senior executives as Senior Management Personnel (SMP) effective July 29, 2026, following an internal restructuring. The company informed the Bombay Stock Exchange and the National Stock Exchange of India Ltd that Balmukund Keshav and Sanjay Singhal have been added to the SMP list pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The disclosure was made in compliance with SEBI Listing Regulations and Part A of Schedule III thereto, read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Pratham Rawal, Company Secretary and Compliance Officer, signed the filing on July 29, 2026.

Appointee Details

The designations reflect the company’s focus on strengthening its technology and regulatory oversight capabilities. Both individuals are existing employees with significant tenure at Jagsonpal Pharmaceuticals Ltd.

Balmukund Keshav brings over 29 years of experience in IT leadership. During his 17-year tenure with Jagsonpal Pharmaceuticals Ltd, he has led digital transformation, ERP implementation, ITGC audits, and enterprise infrastructure management. His expertise covers IT governance, risk, information security, vendor management, and digital process automation.

Sanjay Singhal is a pharmacy professional with a master’s degree from Birla Institute of Technology, Pilani. He possesses 31 years of experience across manufacturing, supply chain, quality, and regulatory affairs. Singhal is also a government-approved technical person for all dosage forms across manufacturing and analytical divisions.

What This Means

The designation of these two executives as SMP formalizes their role in the company’s key decision-making and compliance framework. Under SEBI regulations, Senior Management Personnel are responsible for ensuring compliance with listing obligations and facilitating communication between the board and regulators. The move aligns with standard corporate governance practices following internal structural changes.

No financial impact or remuneration changes were disclosed in the filing. The appointments are administrative in nature, aimed at updating the company’s compliance records to reflect current operational leadership.

Jagsonpal Pharmaceuticals has scheduled a conference call with analysts and investors to discuss its financial results for the first quarter of FY27. The meeting is set to take place on July 30, 2026, at 2:30 PM IST, as part of the company's investor engagement activities.

The discussion will be led by the company's senior management, including Managing Director Manish Gupta, Chief Operating Officer Amrut Medhekar, and Chief Financial Officer Nirav Vora. The event is being hosted by Go India Advisors.

Conference Call Details

Participants are required to pre-register to avoid wait time and join using the Diamond Pass facility. The company has advised attendees to dial in at least 5 to 10 minutes prior to the scheduled start time to ensure timely connection.

For further information regarding the conference call, investors may contact Soumya Chhajed or Sheetal Khanduja via email at soumya@goindiaadvisors.com and sheetal@goindiaadvisors.com , respectively.